Back to results
US 2022/0064622 A1Published application
Methods of using fix polypeptides
AssigneeBioverativ Therapeutics Inc.
InventorsGlenn PIERCE, Samantha TRUEX, Robert T. PETERS, Haiyan JIANG, Mark BRADER
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.
Claims21
1-130. (canceled)
A method of reducing or decreasing an annualized bleeding rate in a human subject with hemophilia B, comprising administering to the subject multiple doses of a pharmaceutical composition comprising:
- (a) a chimeric Factor IX(FIX) polypeptide comprising human FIX and an FcRn binding partner;
- (b) sucrose;
- (c) mannitol;
- and
- (d) polysorbate 20 or polysorbate 80,
- wherein each of the multiple doses comprises 10 IU/kg to 200 IU/kg of the chimeric FIX polypeptide wherein each of the multiple doses is administered at a dosing interval of about 7 days to about 14 days, wherein the annualized bleeding rate of the bleeding episodes is reduced to less than 5;
- and wherein the bleeding episodes are spontaneous bleeding episodes.
4 more elements
Dependencies are inferred from the claim text.